Forte Biosciences Inc Asset Resilience Ratio
Forte Biosciences Inc asset resilience ratio. Forte Biosciences Inc (FBRX) has an Asset Resilience Ratio of 0.00% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See FBRX defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Forte Biosciences Inc (2015–2024)
Asset resilience ratio of Forte Biosciences Inc from 2015 to 2024. This chart shows how Forte Biosciences Inc's Asset Resilience Ratio has changed over time. Read Forte Biosciences Inc debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Forte Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Forte Biosciences Inc total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Forte Biosciences Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Forte Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Forte Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Forte Biosciences Inc Asset Resilience Ratio by Year (2015–2024)
Forte Biosciences Inc asset resilience ratio by year from 2015 to 2024. The table below shows the annual Asset Resilience Ratio data for Forte Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 58.68% | $36.12 Million | $61.56 Million | -5.88pp |
| 2023-12-31 | 64.56% | $25.16 Million | $38.98 Million | +10.94pp |
| 2018-12-31 | 53.62% | $55.27 Million | $103.08 Million | -3.72pp |
| 2017-12-31 | 57.34% | $52.79 Million | $92.07 Million | -15.46pp |
| 2016-12-31 | 72.80% | $25.73 Million | $35.35 Million | -8.84pp |
| 2015-12-31 | 81.64% | $50.76 Million | $62.17 Million | -- |
About Forte Biosciences Inc
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. … Read more